CDNA Stock Overview
Engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CDNA from our risk checks.
My Notes
Capture your thoughts, links and company narrative
CareDx, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.61 |
| 52 Week High | US$34.84 |
| 52 Week Low | US$7.42 |
| Beta | 1.84 |
| 1 Month Change | -7.87% |
| 3 Month Change | -30.44% |
| 1 Year Change | 72.47% |
| 3 Year Change | -54.13% |
| 5 Year Change | -3.92% |
| Change since IPO | 106.10% |
Recent News & Updates
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
Nov 05
CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Sep 29Recent updates
The Market Doesn't Like What It Sees From CareDx, Inc's (NASDAQ:CDNA) Revenues Yet As Shares Tumble 26%
Nov 05CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics
Sep 29CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 34% But Its Business Prospects Need A Lift Too
Aug 01CareDx: Benefiting From Some Certainty
Jul 15Why Investors Shouldn't Be Surprised By CareDx, Inc's (NASDAQ:CDNA) 28% Share Price Plunge
Apr 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 40% But Its Business Prospects Need A Lift Too
Mar 02CareDx, Inc's (NASDAQ:CDNA) Shares Bounce 26% But Its Business Still Trails The Industry
Dec 27CareDx, Inc's (NASDAQ:CDNA) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27Benign Growth For CareDx, Inc (NASDAQ:CDNA) Underpins Its Share Price
Jun 29Analyst Forecasts Just Became More Bearish On CareDx, Inc (NASDAQ:CDNA)
May 16CareDx: Shaking Off First-Mover Disadvantage
Oct 18CareDx: Best Near Cap-Gain Health Diagnostics Prospect Say Market Makers
Aug 08Shareholder Returns
| CDNA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.8% | -5.6% | -3.5% |
| 1Y | 72.5% | -1.5% | 22.1% |
Return vs Industry: CDNA exceeded the US Biotechs industry which returned -1.5% over the past year.
Return vs Market: CDNA exceeded the US Market which returned 22.1% over the past year.
Price Volatility
| CDNA volatility | |
|---|---|
| CDNA Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CDNA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CDNA's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 639 | John Hanna | caredx.com |
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software.
CareDx, Inc Fundamentals Summary
| CDNA fundamental statistics | |
|---|---|
| Market cap | US$1.10b |
| Earnings (TTM) | -US$143.56m |
| Revenue (TTM) | US$312.78m |
3.5x
P/S Ratio-7.7x
P/E RatioIs CDNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDNA income statement (TTM) | |
|---|---|
| Revenue | US$312.78m |
| Cost of Revenue | US$107.07m |
| Gross Profit | US$205.71m |
| Other Expenses | US$349.27m |
| Earnings | -US$143.56m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 65.77% |
| Net Profit Margin | -45.90% |
| Debt/Equity Ratio | 0% |
How did CDNA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 23:33 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CareDx, Inc is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Matthew Sykes | Goldman Sachs |